View profile

FarmaKology Newsletter - Issue #1

FarmaKology Newsletter - Issue #1
By Abdul Menum Ali • Issue #1 • View online

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Sanofi’s type I diabetes drug, Zynquista (sotagliflozin).
Britain’s cost effectiveness body has recommended Takeda’s Adcetris (brentuximab vedotin) for adult patients with CD-30 positive advanced cutaneous T-cell lymphoma (CTCL).
Biogen and Eisai have stopped two global Phase III trials of the Alzheimer’s drug aducanumab, after interim analyses indicated that the agent was ineffective and would not meet the primary endpoint.
The settlement resolves about 25,000 lawsuits, which claimed the companies failed to warn about deadly bleeding episodes caused by the drug.
PBCN Podcast - Guild Pharmacy of the Year 2019 Finalist - Emerald Pharmacy - Pharmacy Business & Career Network Podcast -
Job Opportunities
Did you enjoy this issue?
Abdul Menum Ali

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

If you don't want these updates anymore, please unsubscribe here
If you were forwarded this newsletter and you like it, you can subscribe here
Powered by Revue